EUVIMEDEUVIMED entdecken
Crossref

Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease

Yomna Elghanam, Sujata Purja, Eun Young Kim

Journal of Alzheimer’s Disease · 2024

DOI: 10.3233/jad-240008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Yomna Elghanam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health, Evidence-Based and Clinical Research Laboratory, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seou…. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) is a neurodegenerative disease that imposes economic and societal burden. Biomarkers have played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies which marked a significant milestone for the treatment of AD. The inclusion of biomarkers in AD trials facilitates precise diagnosis, monitors safety, demonstrates target engagement, and supports disease modification.

Objective

This study analyzed the utilization state and trends of biomarkers as endpoints in AD trials.

Methods

In this retrospective study, trials were collected by searching clinicaltrials.gov using the term “Alzheimer”. Primary and secondary outcomes were analyzed separately for each phase.

Results

Among the 1,048 analyzed trials, 313 (29.87%) adopted biomarkers as primary endpoints and 364 (34.73%) as secondary endpoints, mainly in phases 1 and 2. The top three biomarkers adopted as primary endpoints in phases 1, 2, and 3 were amyloid-PET, tau-PET, and MRI. The top three biomarkers adopted as secondary endpoints, in phase 1, were cerebrospinal fluid (CSF) amyloid-β (Aβ), blood Aβ and amyloid-PET; in phase 2, they were MRI, CSF Aβ, and CSF phospho-tau; and in phase 3, they were amyloid PET, MRI, and blood Aβ. There was a statistically significant increase in the adoption of biomarkers as primary endpoints in phase 2 trials ( p = 0.001) and secondary endpoints in phase 3 trials ( p = 0.001).

Conclusions

The growing recognition of the importance of biomarkers in AD trial’ design and drug development is evident by the significant steady increase in biomarkers’ utilization in phases 2 and 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersClinical Trials as TopicHumansRetrospective StudiesPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesMagnetic Resonance ImagingEndpoint DeterminationAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloidbiomarkersclinical trialsdrug developmentendpointtau

Substanzen

Biomarkerstau ProteinsAmyloid beta-PeptidesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Health, Evidence-Based and Clinical Research Laboratory, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea.
  • The Graduate School for Pharmaceutical Industry Management, College of Pharmacy, Chung-Ang University, Seoul, Korea.
  • The Department of Pharmaceutical Regulatory Sciences, Chung-Ang University, Seoul, Korea.

Zitieren

APA

Elghanam, Y., Purja, S., & Kim, E. Y. (2024). Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240008

Vancouver

Elghanam Y, Purja S, Kim EY. Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240008

BibTeX
@article{Elghanam2024,
  author = {Elghanam, Yomna and Purja, Sujata and Kim, Eun Young},
  title = {Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.3233/jad-240008}
}
Kostenlos starten →